Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 224, Issue 1, Pages 273-281Publisher
WILEY
DOI: 10.1002/jcp.22130
Keywords
-
Categories
Funding
- Merck & Co, Inc. (Legacy Schering-Plough Corporation)
Ask authors/readers for more resources
Proprotein convertase subtilisin/kexin type 9 (PCSK9) induces degradation of low-density lipoprotein receptor (LDLR) in the liver. It is being pursued as a therapeutic target for LDL-cholesterol reduction. Earlier genome-wide gene expression studies showed that PCSK9 over-expression in HepG2 cells resulted in up-regulation of genes in cholesterol biosynthesis and down-regulation of genes in stress response pathways; however, it was not known whether these changes were directly regulated by PCSK9 or were secondary to PCSK9-induced changes to the intracellular environment. In order to further understand the biological function of PCSK9 we treated HepG2 cells with purified recombinant wild type (WT) and D374Y gain-of-function PCSK9 proteins for 8, 24, and 48 h, and used microarray analysis to identify genome-wide expression changes and pathways. These results were compared to the changes induced by culturing HepG2 cells in cholesterol-free medium, mimicking the intracellular environment of cholesterol starvation. We determined that PCSK9-induced up-regulation of cholesterol biosynthesis genes resulted from intracellular cholesterol starvation. In addition, we identified novel pathways that are presumably regulated by PCSK9 and are independent of its effects on cholesterol uptake. These pathways included protein ubiquitination, xenobiotic metabolism, cell cycle, and inflammation and stress response. Our results indicate that PCSK9 affects metabolic pathways beyond cholesterol metabolism in HepG2 cells. J. Cell. Physiol. 224: 273-281, 2010. (C) 2010 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available